MBIO Company Profile and Key Details

Q: Who are the executives of MBIO?

Dr. Manuel Litchman M.D.Pres, Chief Executive Officer & DirectorMr. Eliot M. Lurier CPAInterim Chief Financial OfficerDr. Knut NissChief Technology OfficerMr. Scott Smith M.B.A.Executive Director and Head of Alliance & Program ManagementDr. Bruce Dezube M.D.Senior Vice President & Head of Clinical Devel.Ms. Debra Manning SPHRSenior Vice President of HRMr. Rick Bodmer M.S.Vice President & Head of CMC Devel.Mr. Greg Furrow M.S.Interim Chief Technology Officer, Senior Vice President & Head of QualityMr. Matthew Wein J.D.Vice President & Gen. Counsel

NASDAQ : MBIO

Mustang Bio

$0.74

-0.008-1.07%

At Close 4:00 PM

$0.80

0.7411+6.17%

Pre-Market 08:30 PM

62.06

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Mustang Bio, Inc. (MBIO) stock surged +1.81%, trading at $0.75 on NASDAQ, up from the previous close of $0.74. The stock opened at $0.75, fluctuating between $0.73 and $0.76 in the recent session.

Stock Snapshot

0.741

Prev. Close

5.72M

Market Cap

0.73

Day Low

-1.93

P/E Ratio

-0.39

EPS (TTM)

-5.38

Cash Flow per Share

0.75

Open

7.58M

Number of Shares

0.76

Day High

85.52%

Free Float in %

0.01

Book Value

35.5K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	0.75	0.79	0.74	0.74	18.54K
Apr 29, 2026	0.74	0.78	0.73	0.75	45.63K
Apr 28, 2026	0.76	0.78	0.75	0.75	23.32K
Apr 27, 2026	0.75	0.78	0.75	0.76	30.59K
Apr 23, 2026	0.75	0.77	0.75	0.76	5.12K
Apr 22, 2026	0.74	0.77	0.72	0.77	78.74K
Apr 21, 2026	0.76	0.76	0.72	0.72	10.3K
Apr 20, 2026	0.75	0.77	0.68	0.74	106.61K
Apr 17, 2026	0.76	0.79	0.75	0.77	23.94K
Apr 16, 2026	0.77	0.77	0.75	0.76	20.99K
Apr 14, 2026	0.71	0.75	0.71	0.75	42.68K
Apr 13, 2026	0.70	0.75	0.69	0.71	19.61K
Apr 10, 2026	0.74	0.77	0.70	0.70	51.99K
Apr 09, 2026	0.74	0.75	0.74	0.74	11K
Apr 08, 2026	0.78	0.78	0.74	0.75	31.99K
Apr 07, 2026	0.76	0.80	0.72	0.74	19.76K
Apr 06, 2026	0.75	0.76	0.75	0.76	27.8K
Apr 02, 2026	0.74	0.79	0.74	0.78	56.65K
Apr 01, 2026	0.73	0.80	0.73	0.76	45.42K
Mar 31, 2026	0.73	0.74	0.73	0.73	19.55K

Contact Details

Worcester, MA 01605

United States

https://www.mustangbio.com 781 652 4500

About Company

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Company Overview

Mustang Bio, Inc. (NASDAQ:MBIO) closed at $0.75 USD, gaining $0.01 (1.81%) from the previous close of $0.74. The stock is currently mid-range between its 52-week high and low $0.53 and $7.00. With a market capitalization of about $5.72 million, Mustang Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.18). Key stats such as the average daily volume over the past year has been around 163.63 thousand shares, volume is running light vs its 52-week average. Headquartered in Worcester, MA, Mustang Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Manuel Litchman, the company employs approximately 6 people and listed since August 22, 2017. Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 14.69%, SMA50 3.4%, SMA200 -25.23%). The stock’s 14-day RSI is 58.97 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.29% below its high and over 94.12% above its low. Average 10-day trading volume of 33.66 thousand shares is below the 3-month average of 173.13 thousand, indicating normal recent market interest.

Valuation Metrics

Mustang Bio, Inc. trades at a P/E ratio of -2.82, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.57 suggesting the stock is closer to book value. The P/FCF stands at -1.07, also below market averages.

Dividend & Fair Value

Mustang Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.35. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Mustang Bio, Inc. generated EPS of -$1.27 over the past year. Five-year average earnings growth is 51.52%. The latest quarter delivered EPS of -$0.08. The next quarter is forecast at $nan. Next year's EPS is expected at $67.94. Mustang Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended March 19, 2026, missed forecasts by -98.55%. The prior quarter beat by 590.0%. Over the last six quarters, Apple has recorded several small beats. These include -47.13% in May 15, 2024.

Shareholding & Insider Activity

Mustang Bio, Inc. has 6.39 million shares outstanding. The public float is 6.19 million shares, elevated short interest at 2.78% of float. This equals 177.45 thousand shares. The short ratio is 0.56 days. Institutional investors hold 10.57% of the float. Insiders own 4.3%. Litchman Manuel MD holds 1.10 million shares, ROSENWALD LINDSAY A MD has 299.18 thousand shares and Achenbach Brian has 144.73 thousand shares. Over the past six months, insider transactions show net selling. They sold 251.00 shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Mustang Bio has not generated any revenue. Returns are negative, with ROA at -290.85% and ROE at -41952.85%.
On valuation metrics, Mustang Bio trades at a P/E of -2.82, P/S of 0.00 and P/B of 0.57. The current ratio is 2.22 and quick ratio is 2.22. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -31247.56 days , indicating it collects cash faster than it pays suppliers.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Mustang Bio posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $2.23M (margin 0.00%). Operating income was - $50.73M (margin 0.0%). Net income was- $51.60M (EPS - $6.00).
The company ended the quarter with $6.23M in cash and short-term investments, a total debt of $2.50M, and net debt of - $3.74M. Total assets were $17.74M, with equity of $123.00K. Financials further reflected weakness, with operating cash flow of - $49.48M, free cash flow of - $49.59M, and capital expenditures of - $114.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Mustang Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.21%, with price expected at $0.75 by May 14, 2026, within a range of $0.72 to $0.78 3-Month Outlook: Projected rise of 61.94%, reaching $1.20 by July 29, 2026, with a range of $0.94 to $1.41. 1-Year Outlook: Projected loss of -98.65%, with price at $0.01 by April 30, 2027, within a range of $0.00 to $2.25.

Key Takeaways

Mustang Bio, Inc. (NASDAQ:MBIO) shares are flat 4.99% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Mustang Bio, Inc. trading at a premium to the broader market with a P/E of -2.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.93, suggesting 1509.99% upside. Our AI forecast model points to short-term strength (1.21% over two weeks), a medium-term rise (61.94% over three months), and a longer-term loss (-98.65% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Mustang Bio, Inc. (MBIO) stock price?

Mustang Bio, Inc. (NASDAQ: MBIO) stock price is $0.75 in the last trading session. During the trading session, MBIO stock reached the peak price of $0.76 while $0.73 was the lowest point it dropped to. The percentage change in MBIO stock occurred in the recent session was 1.81% while the dollar amount for the price change in MBIO stock was $0.01.

MBIO's industry and sector of operation?

The NASDAQ listed MBIO is part of Biotechnology industry that operates in the broader Healthcare sector. Mustang Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MBIO?

Dr. Manuel Litchman M.D.
Pres, Chief Executive Officer & Director
Mr. Eliot M. Lurier CPA
Interim Chief Financial Officer
Dr. Knut Niss
Chief Technology Officer
Mr. Scott Smith M.B.A.
Executive Director and Head of Alliance & Program Management
Dr. Bruce Dezube M.D.
Senior Vice President & Head of Clinical Devel.
Ms. Debra Manning SPHR
Senior Vice President of HR
Mr. Rick Bodmer M.S.
Vice President & Head of CMC Devel.
Mr. Greg Furrow M.S.
Interim Chief Technology Officer, Senior Vice President & Head of Quality
Mr. Matthew Wein J.D.
Vice President & Gen. Counsel

How MBIO did perform over past 52-week?

MBIO's closing price is 39.55% higher than its 52-week low of $0.53 where as its distance from 52-week high of $7.00 is -89.41%.

How many employees does MBIO have?

Number of MBIO employees currently stands at 6.

Link for MBIO official website?

Official Website of MBIO is: https://www.mustangbio.com

How do I contact MBIO?

MBIO could be contacted at phone 781 652 4500 and can also be accessed through its website. MBIO operates from 377 Plantation Street, Worcester, MA 01605, United States.

How many shares of MBIO are traded daily?

MBIO stock volume for the day was 35.5K shares. The average number of MBIO shares traded daily for last 3 months was 163.63K.

What is the market cap of MBIO currently?

The market value of MBIO currently stands at $5.72M with its latest stock price at $0.75 and 7.58M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	6
Beta	2.18
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MBIO Company Profile and Key Details

Mustang Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook